Summit Materials, Inc. (SUM) At $30.74 Forms Top; Shorts at Xenon Pharmaceuticals (XENE) Lowered By 9.9%

Summit Materials, Inc. (SUM) formed multiple top with $32.89 target or 7.00% above today’s $30.74 share price. Summit Materials, Inc. (SUM) has $3.50B valuation. The stock decreased 0.23% or $0.07 during the last trading session, reaching $30.74. About 1.31M shares traded or 7.99% up from the average. Summit Materials, Inc. (NYSE:SUM) has risen 29.53% since December 24, 2016 and is uptrending. It has outperformed by 12.83% the S&P500.

Xenon Pharmaceuticals Incorporated (NASDAQ:XENE) had a decrease of 9.9% in short interest. XENE’s SI was 179,300 shares in December as released by FINRA. Its down 9.9% from 199,000 shares previously. With 102,200 avg volume, 2 days are for Xenon Pharmaceuticals Incorporated (NASDAQ:XENE)’s short sellers to cover XENE’s short positions. The SI to Xenon Pharmaceuticals Incorporated’s float is 1.6%. The stock decreased 1.96% or $0.05 during the last trading session, reaching $2.5. About 135,647 shares traded or 83.20% up from the average. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has declined 39.94% since December 24, 2016 and is downtrending. It has underperformed by 56.64% the S&P500.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company has market cap of $45.00 million. The firm uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It currently has negative earnings. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency.

Among 5 analysts covering Xenon Pharmaceuticals (NASDAQ:XENE), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Xenon Pharmaceuticals had 14 analyst reports since August 11, 2015 according to SRatingsIntel. As per Wednesday, September 2, the company rating was downgraded by Zacks. The firm has “Buy” rating by Stifel Nicolaus given on Friday, October 21. The rating was upgraded by Zacks on Tuesday, August 11 to “Sell”. The rating was maintained by Jefferies on Monday, September 11 with “Buy”. On Monday, June 12 the stock rating was maintained by Jefferies with “Buy”. Jefferies reinitiated the stock with “Buy” rating in Monday, March 13 report. The firm earned “Buy” rating on Friday, October 30 by Jefferies. Jefferies maintained Xenon Pharmaceuticals Inc. (NASDAQ:XENE) rating on Friday, August 4. Jefferies has “Buy” rating and $500 target. The firm has “Buy” rating by Guggenheim given on Monday, September 26. The rating was maintained by Jefferies on Wednesday, March 9 with “Buy”.

Analysts await Summit Materials, Inc. (NYSE:SUM) to report earnings on February, 28. They expect $0.27 EPS, up 28.57% or $0.06 from last year’s $0.21 per share. SUM’s profit will be $30.75 million for 28.46 P/E if the $0.27 EPS becomes a reality. After $0.72 actual EPS reported by Summit Materials, Inc. for the previous quarter, Wall Street now forecasts -62.50% negative EPS growth.

Among 12 analysts covering Summit Materials (NYSE:SUM), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. Summit Materials had 32 analyst reports since August 17, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, October 10 report. The firm earned “Neutral” rating on Tuesday, October 11 by Goldman Sachs. The firm earned “Buy” rating on Thursday, August 4 by Citigroup. RBC Capital Markets maintained the shares of SUM in report on Tuesday, November 14 with “Buy” rating. Bank of America upgraded the stock to “Buy” rating in Thursday, October 8 report. RBC Capital Markets maintained the stock with “Buy” rating in Friday, August 28 report. The stock of Summit Materials, Inc. (NYSE:SUM) has “Buy” rating given on Friday, January 20 by Suntrust Robinson. Citigroup maintained it with “Buy” rating and $24 target in Monday, April 18 report. Stifel Nicolaus maintained it with “Buy” rating and $35.0 target in Wednesday, September 6 report. The firm has “Neutral” rating given on Wednesday, November 16 by Bank of America.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: